Skip to main content
Premium Trial:

Request an Annual Quote

Berkeley Lights' Beacon Platform

Berkeley Lights has launched its Beacon platform, which accelerates cell line development and empowers immuno-oncology research. The new platform is powered by BLI's OptoSelect technology, which enables the precise movement, positioning, and interaction of cells on an opto-fluidic chip. Its automated workflows can shorten the typical development timeline by as much as three months, the company said. The platform also enables researchers to work at a single cell level with B-cells, multiple types of T-cells, myeloid cells, and other cells of interest.

The Scan

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.

Sequencing Study Leads to Vaccine Target in Bacteria Behind Neonatal Meningitis

Researchers eBioMedicine track down potential vaccine targets with transposon sequencing on mutant bacteria causing neonatal meningitis in mouse models of the disease.

Multiple Myeloma Progression Influenced by Immune Microenvironment Expression

Researchers in NPJ Genomic Medicine compare RNA sequencing profiles of 102,207 individual cells in bone marrow samples from 18 individuals with rapid or non-progressing multiple myeloma.

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.